Content :

Bifidobacterium Breve Plus Description B. breve strains were originally isolated from the feces of human infants. Bifidobacterium parvulorum and Bifidobacterium breve were merged under the name Bifidobacterium breve. B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and requires a prescription.


Appearance


White to light yellow-colored, free-flowing
powder.


Potency


500 billion CFU/g;


Overage provided.


Morphology


It is a
gram-positive, catalase-negative, short rod-shaped bacterium.


Finished formats


Depending on the final product design, dosage, and dosage form, the
product can be positioned according to market needs and target group, such as
bulk powder blends, bulk finished capsules, chewable tablets, stick packs and
other formulations;


Available upon request.


Excipients


Select from one of the following:


Maltodextrin; Inulin; Potato/Wheat/Maize starch;


FOS; XOS; GOS; Stachyose; Polydextrose;


Microcrystalline cellulose (processing aid);


Silicon dioxide (processing aid);


Magnesium stearate (processing aid);


Others
available upon request.


Applications


Dietary Supplements


- Capsules, Powder, Tablets;


Food


- Bars, Powdered Beverages.


Storage


Recommend storage at refrigeration (4 ) or frozen temperature (-18 ) in original, sealed package until processed.


Shelf Life


Shelf life of finished products is
dependent upon excipient, processing and storage conditions.


Handling


Bring powder to room temperature in
original package before use.


Packaging material


Product is packaged in multi-layer, ultra-high
barrier foil film which is heat-sealed.


Package sizes


1kg and 5kg;

.wecare-life.com